Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Participants Following First Line Systemic Anti-cancer Therapy (V943-003, IMDZ-04-1702)
Conditions
Interventions
LV305
G305
+2 more
Locations
29
United States
Mayo Clinic- Scottsdale
Scottsdale, Arizona, United States
University of Arizona Cancer Center
Tucson, Arizona, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
Sarcoma Oncology Center
Santa Monica, California, United States
University of Colorado Cancer Center
Boulder, Colorado, United States
Start Date
September 18, 2018
Primary Completion Date
November 20, 2018
Completion Date
November 20, 2018
Last Updated
April 16, 2020
NCT06713993
NCT07543159
NCT07446322
NCT07489378
NCT06594926
NCT05671510
Lead Sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions